In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.
|Articles|November 5, 2012
FDA expands use of rivaroxaban to treat, reduce recurrence of DVT, PE
FDA has expanded the approved use of oral anticoagulant rivaroxaban (Xarelto, Janssen) to include three new indications: treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and reducing the risk of recurrent DVT and PE following initial treatment.
Advertisement
Advertisement
Related to this article
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.
Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
Advertisement
Advertisement
Trending on Drug Topics
1
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
2
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
3
Pfizer Reports Strong Phase 2 Data for 25-Valent Pediatric PCV
4
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
5